

**To: BUCHAREST STOCK EXCHANGE
FINANCIAL SUPERVISORY AUTHORITY**

CURRENT REPORT

According to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations, and Law no. 24/2017 on issuers of financial instruments and market operations

Report Date: **14 October 2026**

Name of the issuing company: **MED LIFE S.A. ("MedLife" or "the Company")**

Registered Office: **Bucharest, Calea Grivitei, no. 365, district 1, Romania**

Telephone / Fax number: **0374 180 470**

Unique Registration Code at the National Office of Trade Registry: **8422035**

Order number on the Trade Registry: **J1996003709402**

EUID: **ROONRC.J1996003709402**

Subscribed and paid-in share capital: **132,870,492 RON**

Total number of shares: **531,481,968 (out of which 665,983 shares without voting rights and 530,815,985 shares with voting rights)**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category**

Important events to report:

Initiation of share buyback program

MED LIFE S.A. informs shareholders and investors regarding the initiation by the Company of the share buyback program approved by the Extraordinary General Meeting of Shareholders of the Company dated April 30, 2026.

The Company informs shareholders and investors that by decision of the Board of Directors of the Company no. 2 dated October 13, 2026, it was decided to initiate, starting with October 19, 2026, the Company's share buyback program in accordance with the Decision of the Extraordinary General Meeting of Shareholders no. 2 dated April 30, 2026 ("EGMS Decision") - "The Program".

The Program will be conducted and implemented in accordance with the applicable rules and regulations on buyback programs, in particular Article 5 of Regulation (EU) 596/2014 of the European Parliament and of the Council on market abuse and Delegated Regulation (EU) 2016/1052.

Maximum size of the Program

By the EGMS Decision no. 2 of April 30, 2026, the repurchase from the market of a maximum number of 6,732,879 own shares was approved, for a maximum period of 18 months from the date of publication of the Decision in the Official Gazette of Romania.

Purpose of the Program

The shares repurchased under the Program will be offered to the employees and management members of the Company, former or current management members, or former or current employees of some of

MED LIFE S.A.

Registered Office: Bucharest, Calea Grivitei, no. 365, district 1, Romania
Unique Registration Code at the National Office of Trade Registry: 8422035
Order number on the Trade Registry: J40/3709/1996
Subscribed and paid-in share capital: 5,536,270.5 RON



the Company's subsidiaries (namely companies which, at the time of granting, are controlled legal entities of the Company), and / or will be offered in exchange for shares / ownership interests held in the Company's subsidiaries by former or current management members or former or current employees of some of the Company's subsidiaries.

Purchase price of shares under the Program

minimum equal to the market price of a share on the BVB at the time of purchase and (ii) maximum equal to the higher value between the price of the last independent transaction and the highest price at that time of the purchase offer on the BVB, in accordance with the provisions of Article 3, paragraph (2) of Commission's Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programs and stabilization measures. The nominal value of the own shares thus acquired by the Company, including those already in its portfolio, cannot exceed the threshold of 10% of the subscribed share capital of the Company as of the date of the buy-back.

Duration of the Program

The period for which the authorization to carry out the Program was granted is maximum 18 months from the date of publication of the EGMS Decision in the Official Gazette of Romania. The EGMS Decision no. 2 of April 30, 2026 was published in the Official Gazette of Romania, part IV, no. 6676 of September 15, 2026.

Program Intermediary

The Board of Directors of the Company decided to carry out the Program through BT Capital Partners S.A., which will provide intermediation services for the Program.

The volume of shares that the Company will be able to buyback daily

MedLife will not be able to repurchase in a trading day more than 25% of the average daily volume of MedLife shares traded on the regulated market of BVB, calculated according to the following:

The volume of shares that the Company will be able to buyback is determined in accordance with the provisions of art. 3 point (3) (b) of Delegated Regulation (EU) 2016/1052, namely the average daily volume is calculated based on the average daily volume traded during the 20-day trading period preceding the date on which the acquisition takes place. The program is not with a fixed volume.

Mihail Marcu
Chief Executive Officer

Ioana Birsu
Investor Relations Manager